Mediwound (MDWD) Receives a New Rating from a Top Analyst

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Mediwound (MDWD) today and set a price target of $7.00. The company’s shares closed last Wednesday at $4.00.

According to, DeGeeter is a top 100 analyst with an average return of 45.3% and a 53.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Sensei Biotherapeutics, and Cellectar Biosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mediwound with a $7.00 average price target.

See today’s analyst top recommended stocks >>

Based on Mediwound’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.85 million and GAAP net loss of $2.85 million. In comparison, last year the company earned revenue of $4.44 million and had a GAAP net loss of $2.46 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts